Antiretroviral treatment regardless of CD4 count: The universal answer to a contextual question

AIDS Research and Therapy

Volumn 13, Issue 1, 2016, Pages

  Eholié, Serge P ^a,b,c   Badje, Anani ^b,c   Kouame, Gérard M ^c   N'takpe, Jean Baptiste ^c   Moh, Raoul ^a,b,c   Danel, Christine ^b,c   Anglaret, Xavier ^b,c  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Programme PACCI ANRS Research Site   (Côte d’Ivoire)

Author keywords

Early antiretroviral treatment; Randomized controlled trial

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KAPOSI SARCOMA; MORBIDITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TUBERCULOSIS; BLOOD; DRUG ADMINISTRATION; IMMUNOLOGY; MORTALITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; MORBIDITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84979258427     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/s12981-016-0111-1     Document Type: Review

References (33)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-33.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734-9.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60.
4. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333(7):450-1.
5. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94(24):13193-7.
6. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295-300.
7. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288(2):222-35.
8. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367(9527):1981-9.
9. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-96.
10. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133-44.
11. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009;200(6):973-83.
12. Dart Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS. 2008;22(2):237-47.
13. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-26.
14. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-63.
15. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257-65.
16. Eholie SP, Vella S, Anglaret X. Commentary: Antiretroviral therapy initiation criteria in low resource settings-from 'when to start' to 'when not to start'. AIDS. 2014;28(Suppl 2):S101-4.
17. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. http://www.whoint/hiv/pub/guidelines/earlyrelease-arv/en/.
18. EACS. Guidelines, Version 8.0. http://www.eacsocietyorg/files/guidelines_8_0-english_webpdf.
19. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://www.aidsinfonihgov/contentfiles/lvguidelines/adultandadolescentglpdf.
20. International Antiviral Society-USA Panel. Antiretroviral Treatment of Adult HIV Infection. https://www.iasusaorg/content/antiretroviral-treatment-adult-hiv-infection-0 (2015).
21. Insight START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
22. ANRS Temprano 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-22.
23. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281-90.
24. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
25. UNAIDS. The gap report. http://www.unaidsorg/sites/default/files/media_asset/UNAIDS_Gap_report_enpdf.
26. Siedner M, Ng C, Bassett I, Katz I, Bangsberg D, Tsai A. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. Clin Infect Dis. 2015;60(7):1120-7.
27. WHO. Consolidated guidelines on HIV testing services. http://www.whoint/hiv/pub/guidelines/hiv-testing-services/en/.
28. Abdool Karim SS. Overcoming impediments to global implementation of early antiretroviral therapy. N Engl J Med. 2015;373(9):875-6.
29. Vella S. End of AIDS on the horizon, but innovation needed to end HIV. Lancet HIV. 2015;2(3):e74-5.
30. Flexner C, Plumley B. Brown Ripin DH. Treatment optimization: an outline for future success. Curr Opin HIV AIDS. 2013;8(6):523-7.
31. Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 2013;9(10):e1003691.
32. UNAIDS. 90-90-90-An ambitious treatment target to help end the AIDS epidemic. http://www.unaidsorg/en/resources/documents/2014/90-90-90.
33. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9(6):446-69.